免疫治疗新进展参考幻灯片.ppt

主要终点 PFS 、次要终点 ORR NIVO + IPI (N = 314) NIVO (N = 316) IPI (N = 315) Median PFS, months (95% CI) 11.5 (8.9 – 16.7) 6.9 (4.3 – 9.5) 2.9 (2.8 – 3.4) HR (95% CI) vs IPI 0.42 (0.31 – 0.57)* 0.57 (0.43 – 0.76)* -- HR (95% CI) vs NIVO 0.74 (0.60 – 0.92)** -- -- ORR (95% CI) 57.6% (52.0 – 63.2)* 43.7% (38.1 – 49.3)* 19.0% (14.9 – 23.8) CR rate 11.5% 8.9% 2.2% 31 Jedd D. Wolchok, et al. 2015 ASCO Annual Meeting abstr LBA1. * P 0.00001 vs IPI. **Study not statistically powered for this comparison. 2020/2/28 研究结论 ? NIVO + IPI 及 NIVO 单药 临床疗效优于 IPI 单药 ? NIVO + IPI 与 NIVO 单药结果对比提示二者具有疗效互补作用 ? NIVO +

文档评论(0)

1亿VIP精品文档

相关文档